TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

~ Additional Data Readouts and Initiation of Pivotal Trials for Inhaled Tacrolimus and Voriconazole Programs Expected in 2H 2021 ~ Multiple Ascending Dose (MAD) Study Demonstrates Inhaled Tacrolimus Inhalation Powder Achieves Blood Levels Sufficient for Efficacious Immunosuppression ~ Formation of Scientific Advisory Board to Enable Continued Innovation and Clinical Development ~ Partnerships with Pharma, Academic Institutions and Government Continue to Advance

Daniel Carlson

August 12, 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

2 COMMENTS

Peter August 13, 2021 at 9:48 am

You need to login to view this content.

Reply
- Daniel Carlson August 14, 2021 at 8:51 am
  
  You need to login to view this content.
  
  Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.